Teva Pharmaceutical Industries (TEVA) Minority Interest (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Minority Interest for 18 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Minority Interest fell 42.86% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at $4.0 million (down 42.86% YoY), and the FY2025 full-year result was $4.0 million, down 98.82% from the prior year.
• Minority Interest was little changed at $4.0 million in Q2 2026 per TEVA's latest filing, from $4.0 million in the prior quarter.
• Across five years, Minority Interest topped out at $916.0 million in Q1 2022 and bottomed at $4.0 million in Q3 2025.
• Historically, Minority Interest has averaged $389.9 million across 5 years, with a median of $329.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Minority Interest slipped 6.05% in 2022, then tumbled 98.82% in 2025.
• Over 5 years, Minority Interest stood at $794.0 million in 2022, then declined by 21.91% to $620.0 million in 2023, then plunged by 45.16% to $340.0 million in 2024, then sank by 98.82% to $4.0 million in 2025, then changed by 0.0% to $4.0 million in 2026.
• According to Business Quant data, Minority Interest over the past three periods registered $4.0 million, $4.0 million, and $4.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.